KR0179990B1 - Tetrahydrofuran antifungals - Google Patents

Tetrahydrofuran antifungals Download PDF

Info

Publication number
KR0179990B1
KR0179990B1 KR1019960703319A KR19960703319A KR0179990B1 KR 0179990 B1 KR0179990 B1 KR 0179990B1 KR 1019960703319 A KR1019960703319 A KR 1019960703319A KR 19960703319 A KR19960703319 A KR 19960703319A KR 0179990 B1 KR0179990 B1 KR 0179990B1
Authority
KR
South Korea
Prior art keywords
independently
ester
tetrahydrofuran antifungals
polyestherester
antifungals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019960703319A
Other languages
English (en)
Korean (ko)
Inventor
Anil K Saksena
Viyyor M Girijavallabhan
Raymond G Lovey
Russell E Pike
Haiyan Wang
Yi-Tsung Liu
Ashit K Ganguly
Frank Bennett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22622452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR0179990(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of KR0179990B1 publication Critical patent/KR0179990B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Lubricants (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
KR1019960703319A 1993-12-21 1996-06-21 Tetrahydrofuran antifungals Expired - Lifetime KR0179990B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17108393A 1993-12-21 1993-12-21
PCT/US1994/014236 WO1995017407A1 (en) 1993-12-21 1994-12-20 Tetrahydrofuran antifungals

Publications (1)

Publication Number Publication Date
KR0179990B1 true KR0179990B1 (en) 1999-03-20

Family

ID=22622452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960703319A Expired - Lifetime KR0179990B1 (en) 1993-12-21 1996-06-21 Tetrahydrofuran antifungals

Country Status (28)

Country Link
EP (1) EP0736030B1 (enExample)
JP (1) JP2834889B2 (enExample)
KR (1) KR0179990B1 (enExample)
CN (1) CN1064685C (enExample)
AT (1) ATE204875T1 (enExample)
AU (1) AU681753B2 (enExample)
BR (1) BR1100154B1 (enExample)
CA (1) CA2179396C (enExample)
CO (1) CO4520281A1 (enExample)
CZ (1) CZ294823B6 (enExample)
DE (2) DE69428125T2 (enExample)
DK (1) DK0736030T3 (enExample)
ES (1) ES2159623T3 (enExample)
FI (1) FI118470B (enExample)
FR (1) FR06C0009I2 (enExample)
HU (1) HU225062B1 (enExample)
IL (1) IL112081A (enExample)
LU (1) LU91216I2 (enExample)
MY (1) MY130217A (enExample)
NL (1) NL300219I2 (enExample)
NO (2) NO316173B1 (enExample)
NZ (1) NZ278713A (enExample)
PL (1) PL181193B1 (enExample)
PT (1) PT736030E (enExample)
SK (1) SK283035B6 (enExample)
TW (1) TW377349B (enExample)
WO (1) WO1995017407A1 (enExample)
ZA (1) ZA9410142B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT741737E (pt) * 1994-01-24 2000-04-28 Janssen Pharmaceutica Nv Antifungicos do tipo azole soluveis em agua
ES2199291T3 (es) * 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
US5698557A (en) * 1995-06-19 1997-12-16 Schering Corporation Hydroxy-substituted antifungals
WO1997000255A1 (en) * 1995-06-19 1997-01-03 Schering Corporation Tetrahydrofuran antifungals
PL327142A1 (en) * 1995-12-20 1998-11-23 Schering Corp Method of obtaining hydrazides
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
ZA974428B (en) 1996-05-24 1997-11-24 Schering Corp Antifungal composition with enhanced bioavailability.
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
NZ333514A (en) * 1996-06-28 2000-05-26 Schering Corp Oral pharmaceutical composition comprising a triazole antifungal compound
JP2000514057A (ja) * 1996-06-28 2000-10-24 シェーリング コーポレイション 増強されたバイオアベイラビリティを有する抗真菌剤の固溶体
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0938484A1 (en) * 1996-11-12 1999-09-01 Sepracor, Inc. 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole
EP0937071A1 (en) 1996-11-12 1999-08-25 Sepracor, Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
CN1237172A (zh) * 1996-11-12 1999-12-01 塞普拉科公司 2r,4s,r,s－和2s,4r,r,s－羟基伊曲康唑－和羟基沙波康唑衍生物
CA2269616A1 (en) * 1996-11-12 1998-05-22 Gerald J. Tanoury 2r,4s,s,r- and 2s,4r,s,r-hydroxyitraconazole
US5684197A (en) * 1996-12-12 1997-11-04 Schering Corporation Process for preparation of hydrazides
EE03876B1 (et) 1997-02-11 2002-10-15 Janssen Pharmaceutica N.V. Aminohappe estrit sisaldavad asool-antimükootikumid, nende valmistamine ja kasutamine ning neid sisaldavad farmatseutilised kompositsioonid
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
HUP0004616A3 (en) * 1997-09-25 2002-04-29 Schering Corp Hydroxy ester of tetrahydrofurane derivative as prodrug for the corresponding antifungal agent
DK1021439T3 (da) * 1997-10-07 2004-05-10 Schering Corp Krystallinsk antifungal polymorf form
WO1999018111A1 (en) * 1997-10-07 1999-04-15 Schering Corporation Crystalline antifungal glycine ester polymorph
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
CZ20013866A3 (cs) * 1999-05-04 2002-06-12 Janssen Pharmaceutica N. V. Antifungální ethery
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
KR100607742B1 (ko) 2001-04-03 2006-08-01 쉐링 코포레이션 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
EP1511490A4 (en) 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
EP1515703A1 (en) 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ITMI20032020A1 (it) * 2003-10-17 2005-04-18 Italfarmaco Spa Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici
US8084445B2 (en) * 2004-08-13 2011-12-27 Schering-Plough Animal Health Corporation Pharmaceutical formulation
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2011003992A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
WO2011158248A2 (en) * 2010-05-12 2011-12-22 Glenmark Generics Limited Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
CA2798002C (en) * 2010-05-19 2019-12-03 Sandoz Ag Process for the preparation of chiral triazolones
CA2798010C (en) 2010-05-19 2018-09-25 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
WO2011144656A1 (en) * 2010-05-19 2011-11-24 Sandoz Ag Preparation of posaconazole intermediates
RU2588570C2 (ru) * 2010-05-19 2016-07-10 Сандоз Аг Способ получения хиральных гидразидов
RS62583B1 (sr) 2010-06-29 2021-12-31 Merck Sharp & Dohme Formulacije intravenskog rastvora sa posakonazolom, stabilisane supstituisanim beta-ciklodekstrinom
CA2838051C (en) * 2011-06-16 2019-09-24 Sandoz Ag Process for the preparation of a chiral compound
EP2789610A1 (en) 2013-04-10 2014-10-15 Sandoz Ag Purification of Posaconazole Intermediates
EP3024828B1 (en) * 2013-07-25 2017-05-17 Sandoz AG Improved process for the preparation of crystalline form iv of posaconazole
ITMI20132114A1 (it) 2013-12-18 2015-06-19 Djada Pharmaceutical Sa Una forma cristallina di posaconazolo
CN105287403A (zh) * 2014-08-02 2016-02-03 陕西合成药业股份有限公司 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途
CN104370894A (zh) * 2014-10-21 2015-02-25 江苏恒盛药业有限公司 无定型泊沙康唑的制备工艺
PT3227277T (pt) 2014-12-05 2020-04-14 Pulmocide Ltd Composto antimicótico
JP6811727B2 (ja) * 2015-05-21 2021-01-20 プルモシデ リミテド 抗真菌性の４−（４−（４−（（（３ｒ，５ｒ）−５−（（１ｈ−１，２，４−トリアゾール−１−イル）メチル）−５−（２，４−ジフルオロフェニル）テトラヒドロフラン−３−イル）メトキシ）−３−メチルフェニル）ピペラジン−１−イル）−ｎ−（２−ヒドロキシシクロヘキシル）ベンズアミド、又はその医薬として許容し得る塩
CN106317032A (zh) * 2015-06-15 2017-01-11 重庆圣华曦药业股份有限公司 一种制备高纯度的泊沙康唑的方法
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
ES2946734T3 (es) * 2015-09-23 2023-07-25 Biocon Ltd Formas cristalinas del intermedio de posaconazol y procedimiento para la preparación de posaconazol amorfo
CN105606736A (zh) * 2016-01-27 2016-05-25 重庆华邦制药有限公司 分离测定泊沙康唑中间体z1及其有关物质的方法
DK3424911T3 (da) * 2016-03-04 2021-10-11 Zhejiang Ausun Pharmaceutical Co Ltd Posaconazol, sammensætning, intermediat, fremstillingsfremgangsmåde derfor og anvendelser deraf
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
US11185548B2 (en) 2016-12-23 2021-11-30 Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN106967054A (zh) * 2017-03-30 2017-07-21 成都绿林科技有限公司 一种泊沙康唑的制备方法
CN106883221A (zh) * 2017-04-17 2017-06-23 兰州大学 一种无定形泊沙康唑及其制备方法
CN108341754A (zh) * 2018-03-12 2018-07-31 扬子江药业集团有限公司 泊沙康唑杂质及其制备方法和用途
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途
CN112778369B (zh) * 2019-11-05 2024-01-26 华创合成制药股份有限公司 一种三唑类衍生物及其制备方法和用途
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
CN113666915B (zh) * 2021-08-27 2022-08-16 江苏海洋大学 一种泊沙康唑中间体的制备方法
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
EP0318214B1 (en) * 1987-11-20 1994-12-14 Schering Corporation Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals

Also Published As

Publication number Publication date
NL300219I1 (nl) 2006-04-03
CO4520281A1 (es) 1997-10-15
AU1512795A (en) 1995-07-10
NO962616L (no) 1996-08-07
CA2179396A1 (en) 1995-06-29
SK82696A3 (en) 1997-03-05
FR06C0009I2 (enExample) 2006-12-29
CN1064685C (zh) 2001-04-18
ATE204875T1 (de) 2001-09-15
DE69428125T2 (de) 2002-05-02
NZ278713A (en) 1997-12-19
NO962616D0 (no) 1996-06-20
DE122006000004I2 (de) 2007-03-29
PT736030E (pt) 2002-01-30
FI962577A0 (fi) 1996-06-20
BR1100154B1 (pt) 2013-11-26
ES2159623T3 (es) 2001-10-16
LU91216I2 (en) 2006-03-27
JPH09500658A (ja) 1997-01-21
JP2834889B2 (ja) 1998-12-14
HU225062B1 (en) 2006-05-29
DE122006000004I1 (de) 2006-04-27
WO1995017407A1 (en) 1995-06-29
FI118470B (fi) 2007-11-30
IL112081A0 (en) 1995-03-15
CN1142828A (zh) 1997-02-12
NL300219I2 (nl) 2006-05-01
NO316173B1 (no) 2003-12-22
IL112081A (en) 2001-08-26
HUT75879A (en) 1997-05-28
NO2006002I2 (no) 2011-03-07
NO2006002I1 (no) 2006-02-20
FI962577L (fi) 1996-06-20
DK0736030T3 (da) 2001-10-29
AU681753B2 (en) 1997-09-04
SK283035B6 (sk) 2003-02-04
ZA9410142B (en) 1996-05-02
EP0736030A1 (en) 1996-10-09
TW377349B (en) 1999-12-21
PL181193B1 (pl) 2001-06-29
MY130217A (en) 2007-06-29
FR06C0009I1 (enExample) 2006-05-19
HK1008820A1 (en) 1999-05-21
CZ180596A3 (en) 1997-01-15
CZ294823B6 (cs) 2005-03-16
DE69428125D1 (de) 2001-10-04
CA2179396C (en) 2001-04-17
EP0736030B1 (en) 2001-08-29
PL315169A1 (en) 1996-10-14
HU9601709D0 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
KR0179990B1 (en) Tetrahydrofuran antifungals
MX9701229A (es) Antifungicos de tetrahidrofurano.
CA2150287A1 (en) Agent for treating hepato-biliary diseases
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
DE69637380D1 (en) Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
MX9804046A (es) 6-0-metil eritromicina d y proceso para hacerla.
AU6257396A (en) Tetrahydrofuran antifungals
AU8226891A (en) Benzopyran derivative, production thereof, and pharmaceutical composition containing the same
AU8889998A (en) Water soluble analogs and prodrugs of paclitaxel
WO1990012577A3 (en) Topical anti-angiogenic as hair growth inhibitors
CA2511753A1 (en) Phospholipid derivatives
CA2208032A1 (en) Substituted amidinonaphthyl ester derivative
CA2304624A1 (en) Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent
BR9508521A (pt) Inibição da biossintese de leucotrienos com derivados de uréia
CO4770982A1 (es) Nuevas formulaciones

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960621

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19960712

Comment text: Request for Examination of Application

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980903

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011023

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20021029

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20031030

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041011

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20051007

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20061013

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20071005

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20081007

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20091012

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20101029

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20111028

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20121030

Start annual number: 15

End annual number: 15

FPAY Annual fee payment

Payment date: 20131030

Year of fee payment: 16

PR1001 Payment of annual fee

Payment date: 20131030

Start annual number: 16

End annual number: 16

FPAY Annual fee payment

Payment date: 20140929

Year of fee payment: 17

PR1001 Payment of annual fee

Payment date: 20140929

Start annual number: 17

End annual number: 17

EXPY Expiration of term
PC1801 Expiration of term